1 week Ago By ABMN Staff
Orion Portfolio Solutions LLC lowered its stake in Maravai LifeSciences Holdings, Inc. ( NASDAQ:MRVI – Free Report ) by 28.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The fund owned 96,692 shares of the company’s stock after selling 39,057 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Maravai LifeSciences were worth $527,000 at the end of the most recent quarter. A number of other large investors have also added to or reduced their stakes in the stock.
Performa Ltd US LLC lifted its holdings in shares of Maravai LifeSciences by 614.3% during the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after buying an additional 4,300 shares during the period.
FNY Investment Advisers LLC lifted its holdings in Maravai LifeSciences by 600.0% in the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after acquiring an additional 6,000 shares during the period.
Farther Finance Advisors LLC boosted its position in Maravai LifeSciences by 3,541.4% in the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock worth $56,000 after purchasing an additional 9,916 shares during the last quarter.
Cibc World Markets Corp bought a new stake in shares of Maravai LifeSciences during the 4th quarter valued at about $56,000. Finally, Atria Investments Inc purchased a new stake in shares of Maravai LifeSciences during the 4th quarter valued at about $58,000. Institutional investors own 50.
25% of the company’s stock. Insider Buying and Selling at Maravai LifeSciences In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.
03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.
54. This represents a 12.98 % decrease in their ownership of the stock.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Insiders own 0.63% of the company’s stock.
Analyst Ratings Changes Read Our Latest Stock Report on MRVI Maravai LifeSciences Stock Performance NASDAQ:MRVI opened at $1.99 on Tuesday. The stock has a 50-day moving average price of $3.
33 and a 200 day moving average price of $5.28. The stock has a market capitalization of $506.
13 million, a P/E ratio of -1.21 and a beta of 0.18.
Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.78 and a 12-month high of $11.
56. The company has a current ratio of 10.74, a quick ratio of 9.
94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences Profile ( Free Report ) Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.
The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. Featured Articles Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc.
( NASDAQ:MRVI – Free Report ). Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
